Hansoh Pharmaceutical Group Company Limited (3KY.F)

1.8200 -0.0400 (-2.15%) As of 09:59AM CEST. Market open.

Hansoh Pharmaceutical Group Company Limited

287 Xiangke Road
Pudong New District
Shanghai 201210
China
86 40 0828 5227
https://www.hspharm.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 9,123

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Huijuan Zhong	Chairlady, CEO & President	1.44M	N/A	1961
Mr. Aifeng Lyu	Executive Director	327.05k	N/A	1977
Ms. Yuan Sun	Executive Director	888.06k	N/A	1987
Mr. Min Hu	VP & CFO	N/A	N/A	1977
Mr. Gongzheng Wu	Senior Vice President	N/A	N/A	1971
Ms. Chunhua Zhong	Senior Vice President	N/A	N/A	1975
Mr. Chuanhe Xu	Senior Vice President	N/A	N/A	1964
Mr. Rudi Bao	Senior Vice President	N/A	N/A	1964
Mr. Weiyong Sun	Chief Commercial Officer	N/A	N/A	1971
Mr. Qiong Wu	Chief Medical Officer	N/A	N/A	1969

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infectives, central nervous system diseases, metabolic diseases, and other therapeutic areas. Its principal products include Mailingda, Ameile, Hansoh Xinfu, Fulaimei, Hengmu, Xinwei, Tanneng, Ameining, Oulanning, Ailanning, Zetan, Ruibote, Fulaidi, Puruian, Fulairui, Pulaile, Zefei, Xinmei, Xintai, and Gainuo drugs, as well as XINYUE and Hengsen. The company serves pharmaceutical product distributors. It has a collaborations with NiKang Therapeutics to develop and commercialize NKT2152; TiumBio to develop and commercialize TU2670 for the treatment of endometriosis, uterine fibroids and other indications; Global Health Drug Discovery Institute to develop, manufacture, and commercialize the GDI-4405 series of anti-novel coronavirus; KiOmed Pharma SA to develop and commercialize KiOmedinevsOne for the treatment of osteoarthritis; and Biotheus Inc. to develop and commercialize PM1080. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Corporate Governance

Hansoh Pharmaceutical Group Company Limited’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.